Results 61 to 70 of about 1,229,815 (249)

Contemporary and Emerging Therapies in the Management of Refractory Angina: A Clinical Review

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Refractory angina (RA) represents a growing challenge in clinical cardiology, particularly in patients with obstructive coronary artery disease (CAD) who remain symptomatic despite optimal medical therapy and who are not candidates for revascularization.
Alex Angers‐Goulet   +4 more
wiley   +1 more source

Forecasting heart failure: Seasonal alignment of heart failure outcomes in New York

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 819-831, April 2025.
Abstract Background Seasonal variations have been observed in heart failure (HF) hospitalization. Numerous explanatory mechanisms have been proposed, but no prior studies have examined potential contributors directly. Our objective was to identify specific factors that could contribute to seasonal variability using a large longitudinal dataset of HF ...
Prerna Gupta   +5 more
wiley   +1 more source

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio   +10 more
wiley   +1 more source

The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 980-997, April 2025.
Abstract Heart failure (HF) creates a considerable clinical, humanistic and economic burden on patients and caregivers as well as on healthcare systems. To attenuate the significant burden of HF, there is a need for enhanced management of patients with HF.
Javed Butler   +8 more
wiley   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller   +8 more
wiley   +1 more source

The Circadian Variation of Atrial Defibrillation Thresholds

open access: yesJournal of Interventional Cardiac Electrophysiology, 2003
A circadian variation exists for ventricular defibrillation thresholds (DFTs) with a morning peak and a corresponding decrease in therapy success rates from implantable cardioverter defibrillators. Such a variation in atrial DFTs may have implications for the timing of internal cardioversion of atrial arrhythmias. The aim of this study was therefore to
Mitchell, Andrew R.   +3 more
openaire   +2 more sources

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani   +11 more
wiley   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul   +13 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Response Time Threshold for Predicting Outcomes of Patients with Out-of-Hospital Cardiac Arrest

open access: yesEmergency Medicine International, 2021
Ambulance response time is a prognostic factor for out-of-hospital cardiac arrest (OHCA), but the impact of ambulance response time under different situations remains unclear.
Ling Hsuan Huang   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy